Motawi Tarek M K, Mahdy Soliman G, El-Sawalhi Maha M, Ali Eman N, El-Telbany Rania Farag A
a Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
b Cardiology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Can J Physiol Pharmacol. 2018 Jan;96(1):38-44. doi: 10.1139/cjpp-2017-0272. Epub 2017 Sep 28.
Cardiovascular diseases (CVD) are the leading cause of death in the diabetic population. Obesity is a serious problem that has been linked with CVD and diabetes via a variety of adipokines. The aims of this study were to evaluate and correlate circulating chemerin, apelin, vaspin, and omentin-1 levels in obese type 2 diabetic Egyptian patients with coronary artery stenosis (CAS), and to assess their usefulness as noninvasive diagnostic biomarkers. Chemerin, apelin, vaspin, and omentin-1 levels were determined by enzyme immunoassay in coronary artery disease (CAD) I patients (45 non-obese, nondiabetic with CAS), CAD II patients (45 obese, diabetic with CAS), and 30 controls. Patients in CAD I and CAD II groups exhibited higher levels of chemerin and apelin together with lower levels of vaspin and omentin-1 than in controls. These alterations were more significant in CAD II than in CAD I patients. Additionally, adipokine levels were individually correlated with each other and with certain biochemical variables. Moreover, chemerin and vaspin levels could differentiate CAD II patients from CAD I and controls. Alterations of these adipokines may play a crucial role in the pathogenesis of CAS in obese type 2 diabetic Egyptian patients. Chemerin and vaspin could be used as markers to support diagnosis of CAS.
心血管疾病(CVD)是糖尿病患者死亡的主要原因。肥胖是一个严重问题,它通过多种脂肪因子与心血管疾病和糖尿病相关联。本研究的目的是评估埃及肥胖2型糖尿病合并冠状动脉狭窄(CAS)患者循环中趋化素、脂联素、内脏脂肪素和网膜素-1的水平并进行相关性分析,同时评估它们作为无创诊断生物标志物的效用。通过酶免疫测定法测定冠状动脉疾病(CAD)I组患者(45例非肥胖、非糖尿病合并CAS)、CAD II组患者(45例肥胖、糖尿病合并CAS)以及30名对照者的趋化素、脂联素、内脏脂肪素和网膜素-1水平。CAD I组和CAD II组患者的趋化素和脂联素水平高于对照组,而内脏脂肪素和网膜素-1水平低于对照组。这些改变在CAD II组患者中比CAD I组患者更显著。此外,脂肪因子水平之间以及与某些生化变量之间存在个体相关性。而且,趋化素和内脏脂肪素水平可将CAD II组患者与CAD I组患者及对照组区分开来。这些脂肪因子的改变可能在埃及肥胖2型糖尿病患者CAS的发病机制中起关键作用。趋化素和内脏脂肪素可作为支持CAS诊断的标志物。